These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30745397)

  • 1. Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.
    Robertson GT; Ektnitphong VA; Scherman MS; McNeil MB; Dennison D; Korkegian A; Smith AJ; Halladay J; Carter DS; Xia Y; Zhou Y; Choi W; Berry PW; Mao W; Hernandez V; Alley MRK; Parish T; Lenaerts AJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.
    Lanoix JP; Ioerger T; Ormond A; Kaya F; Sacchettini J; Dartois V; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):735-43. PubMed ID: 26574016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
    Lanoix JP; Lenaerts AJ; Nuermberger EL
    Dis Model Mech; 2015 Jun; 8(6):603-10. PubMed ID: 26035868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
    Ramey ME; Kaya F; Bauman AA; Massoudi LM; Sarathy JP; Zimmerman MD; Scott DWL; Job AM; Miller-Dawson JA; Podell BK; Lyons MA; Dartois V; Lenaerts AJ; Robertson GT
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0059723. PubMed ID: 37791784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.
    Dutta NK; Karakousis PC
    Int J Antimicrob Agents; 2014 Dec; 44(6):564-6. PubMed ID: 25270632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
    Harper J; Skerry C; Davis SL; Tasneen R; Weir M; Kramnik I; Bishai WR; Pomper MG; Nuermberger EL; Jain SK
    J Infect Dis; 2012 Feb; 205(4):595-602. PubMed ID: 22198962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.
    Xu J; Lu Y; Fu L; Zhu H; Wang B; Mdluli K; Upton AM; Jin H; Zheng M; Zhao W; Li P
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):1119-25. PubMed ID: 22691726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.
    Tonge PJ; Kisker C; Slayden RA
    Curr Top Med Chem; 2007; 7(5):489-98. PubMed ID: 17346194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis.
    Irwin SM; Driver E; Lyon E; Schrupp C; Ryan G; Gonzalez-Juarrero M; Basaraba RJ; Nuermberger EL; Lenaerts AJ
    Dis Model Mech; 2015 Jun; 8(6):591-602. PubMed ID: 26035867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic isoniazid resistance and associated mutations in pediatric tuberculosis.
    Jhanjhria S; Kashyap B; Gomber S; Gupta N; Hyanki P; Singh NP; Khanna A; Sharma AK
    Indian J Tuberc; 2019 Oct; 66(4):474-479. PubMed ID: 31813434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.
    Flint L; Korkegian A; Parish T
    PLoS One; 2020; 15(11):e0239354. PubMed ID: 33201882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.
    Driver ER; Ryan GJ; Hoff DR; Irwin SM; Basaraba RJ; Kramnik I; Lenaerts AJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3181-95. PubMed ID: 22470120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.
    Irwin SM; Gruppo V; Brooks E; Gilliland J; Scherman M; Reichlen MJ; Leistikow R; Kramnik I; Nuermberger EL; Voskuil MI; Lenaerts AJ
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4026-34. PubMed ID: 24798275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.
    Henao-Tamayo M; Obregón-Henao A; Creissen E; Shanley C; Orme I; Ordway DJ
    Clin Vaccine Immunol; 2015 Jan; 22(1):91-8. PubMed ID: 25392011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The characteristics of the sensitivity of Mycobacterium tuberculosis to rifampicin and isoniazid through determination of mutations in the genes rpoB, katG, inhA, oxyR, and kasA by different molecular biological assays].
    Skotnikova OI; Galkina KIu; Nosova EIu; Krasnova MA; Moroz AM
    Probl Tuberk Bolezn Legk; 2005; (8):42-5. PubMed ID: 16209020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a cofactor-independent inhibitor of
    Xia Y; Zhou Y; Carter DS; McNeil MB; Choi W; Halladay J; Berry PW; Mao W; Hernandez V; O'Malley T; Korkegian A; Sunde B; Flint L; Woolhiser LK; Scherman MS; Gruppo V; Hastings C; Robertson GT; Ioerger TR; Sacchettini J; Tonge PJ; Lenaerts AJ; Parish T; Alley M
    Life Sci Alliance; 2018 Jun; 1(3):e201800025. PubMed ID: 30456352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Berberine as an Adjunct to TB Treatment.
    Ozturk M; Chia JE; Hazra R; Saqib M; Maine RA; Guler R; Suzuki H; Mishra BB; Brombacher F; Parihar SP
    Front Immunol; 2021; 12():656419. PubMed ID: 34745081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
    Li W; Obregón-Henao A; Wallach JB; North EJ; Lee RE; Gonzalez-Juarrero M; Schnappinger D; Jackson M
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5198-207. PubMed ID: 27297488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.